RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer

This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.

Inclusion Criteria:

1. Patients with stage IV breast cancer
2. Patients with HER2 positive status
3. Patients that received Inetetamab
4. Patients that began Inetetamab therapy prior to June 30, 2021.

Exclusion Criteria:

Patients treated with an investigational anticancer agent Inetetamab